Obesity

In a Healio exclusive, Andres J. Acosta, MD, PhD, highlights data demonstrating that the MyPhenome test may serve as a biomarker to determine whether a patient with obesity will be a “good responder” to semaglutide.

Adults with overweight or obesity lost more weight with the GIP/GLP-1 dual agonist tirzepatide than the GLP-1 receptor agonist semaglutide, according to findings published in JAMA Internal Medicine.

Higher BMI during early adulthood was associated with an elevated risk for CV outcomes, like heart disease and stroke, among adults aged 35 to 70 years, according to a study published in The Lancet Public Health.

People with type 2 diabetes who use a GLP-1 receptor agonist have a lower risk for 10 types of obesity-associated cancer compared with those who use insulin, according to data published in JAMA Network Open.

Adults with diabetes or obesity using semaglutide may have an increased risk for nonarteritic anterior ischemic optic neuropathy, a common form of optic neuropathy, according to data published in JAMA Ophthalmology.

In patients with obesity, gastric bypass surgery plus a very low-energy diet reduced major atherogenic blood lipids to a greater degree than a very low-energy diet alone at 6 weeks, according to the results of the COCKTAIL trial.

Published results showed exercise in combination with glucagon-like peptide-1 receptor agonist treatment may be an effective weight loss strategy that preserves clinically relevant site-specific bone mineral density.

This year’s American Society for Nutrition Scientific Sessions and Annual Meeting will take place in person in Chicago from June 29 to July 2.

A 5:2 intermittent fasting diet combined with meal replacement resulted in greater weight loss and better glycemic control compared with antidiabetic medications in patients with early-stage type 2 diabetes, data from the EARLY study showed.

ORLANDO — Semaglutide reduces risk for cardiovascular events among adults with overweight or obesity and preexisting cardiovascular disease, regardless of baseline HbA1c or change in HbA1c, according to data from the SELECT trial.